Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02203773
Title Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie

acute myeloid leukemia


Decitabine + Venetoclax

Azacitidine + Venetoclax

Age Groups: senior
Covered Countries USA

No variant requirements are available.